Volume 6.15 | May 1

Prostate Cell News 6.15 May 1, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
Combined Chemotherapy and Immunotherapy Shows Promise for Advanced Prostate Cancers
Researchers found that blocking or removing immune-suppressing cells allowed a special type of chemotherapy—and the immune cells it activates—to destroy prostate tumors. This novel combination therapy, termed chemoimmunotherapy, achieved near complete remission in mouse models of advanced prostate cancer. [Press release from University of California, San Diego discussing online prepublication in Nature]
Press Release | Abstract
Development of Simplified and Defined Cell Culture for hPSCs - Watch Now!
PUBLICATIONS (Ranked by impact factor of the journal)

Inhibition of Plk1 Represses Androgen Signaling Pathway in Castration-Resistant Prostate Cancer
Scientists assessed the effects of polo-like kinase 1 (Plk1) on androgen receptor (AR) signaling in both androgen-dependent and androgen-independent prostate cancer cells. They demonstrated that the expression level of Plk1 correlated with tumorigenicity and that inhibition of Plk1 caused reduction of AR expression and AR activity. [Cell Cycle] Abstract

Resveratrol Activates Autophagic Cell Death in Prostate Cancer Cells via Downregulation of STIM1 and the mTOR Pathway
Investigators showed that resveratrol (RSV) activated autophagic cell death in PC3 and DU145 cells, which was dependent on stromal interaction molecule 1 (STIM1) expression. RSV treatment decreased STIM1 expression in a time-dependent manner and attenuated STIM1 association with TRPC1 and Orai1. [Mol Carcinog] Full Article

Adipocyte-Derived Monocyte Chemotactic Protein-1 (MCP-1) Promotes Prostate Cancer Progression through the Induction of MMP-2 Activity
Scientists investigated the biological role of MCP-1 secreted from adipocytes for prostate cancer cells. To characterize the physiological function of MCP-1 in the conditioned medium, they performed an MTT-assay, a wound-healing and invasion assay with anti-MCP-1 antibody using three prostate cancer cell lines: DU145, LNCaP, and PC-3. [Prostate] Abstract

Metformin Represses Androgen-Dependent and Androgen-Independent Prostate Cancers by Targeting Androgen Receptor
Metformin treatment reduced cell viability and enhanced apoptosis for the androgen-dependent LNCaP and the androgen-independent 22RV1 cell lines and additive effects were observed when LNCaP cells were treated with combined metformin and bicalutamide. Metformin down-regulated full-length androgen receptor protein in LNCaP cells. [Prostate] Abstract

MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer
The authors investigated the role of microRNA (miRNA)-302a in prostate cancer (PCa). Cell proliferation and cell cycle analysis were performed on PCa cells that stably expressed miRNA-302a. [PLoS One] Full Article

mLST8 Promotes mTOR-Mediated Tumor Progression
Knockdown of mLST8 significantly suppressed mTORC1 and mTORC2 complex formation, and it also inhibited tumor growth and invasiveness in human colon carcinoma and prostate cancer cells. [PLoS One] Full Article

Increased Acid Ceramidase Expression depends on Upregulation of Androgen-Dependent Deubiquitinases, USP2, in a Human Prostate Cancer Cell Line, LNCaP
USP2 siRNA decreased acid ceramidase (ACDase protein), while USP2 overexpression increased ACDase protein of LNCaP cells. However, SKP2, an ubiquitin E3 ligase, known to be active in prostate cancer, did not affect androgen-dependent ACDase expression in LNCaP cells. [J Biochem] Abstract

Docetaxel in Combination with Octreotide Shows Synergistic Apoptotic Effect by Increasing SSTR2 and SSTR5 Expression Levels in Prostate and Breast Cancer Cell Lines
Researchers investigated the possible synergistic apoptotic effects of docetaxel in combination with octreotide in prostate and breast cancer cell lines. [Cancer Chemother Pharmacol] Abstract


A Randomized Phase II Trial of Sipuleucel-T with Concurrent vs Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration Resistant Prostate Cancer
This Phase II open-label study evaluated the effect of concurrent or sequential administration of abiraterone acetate plus prednisone on sipuleucel-T manufacture and immune responses in metastatic castration-resistant prostate cancer patients. [Clin Cancer Res] Abstract | Full Article

AZD3514, an Oral Selective Androgen Receptor Down-Regulator in Patients with Castration-Resistant Prostate Cancer – Results of Two Parallel First-In-Human Phase I Studies
In study 1 and 2, castration-resistant prostate cancer patients were initially recruited into a once daily oral schedule. In study 1, pharmacokinetic assessments led to twice daily dosing to increase exposure. Study 2 explored a once daily schedule. [Invest New Drugs] Abstract

FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours
The Oncogene ERG: A Key Factor in Prostate Cancer
The authors review E-26 transformation-specific-related gene (ERG)’s structure and function, and its role in prostate cancer. They also discuss potential new therapies that are based on targeting ERG. [Oncogene] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Target Cancer Metabolism
AACR Recognizes Research Team that Developed Treatment for Late-Stage Prostate Cancer
The American Association for Cancer Research (AACR) will award the ninth annual AACR Team Science Award to the Designing Androgen Receptor Inhibitors Team from Memorial Sloan Kettering Cancer Center and the University of California, Los Angeles. The team is being honored for their collective work in discovering and developing the novel antiandrogen enzalutamide for the treatment of metastatic castration-resistant prostate cancer. [American Association for Cancer Research] Press Release

CPRIT Awards Two New Academic Research Grants
The Cancer Prevention and Research Institute of Texas (CPRIT) awarded two grants through its academic research program. The grants, totaling six million dollars, support the recruitment of two top cancer scientists to academic institutions in Texas, including a promising emerging researcher pursuing her first faculty appointment and an outstanding early-stage researcher. [CPRIT] Press Release

From our sponsor:
Free Cell Stem Cell wallchart – Directed Differentiation of ESCs and iPSCs.
Request your copy.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cells: From Robert Hooke to Cell Therapy – A 350 Year Journey
October 5-6, 2015
London, United Kingdom

Visit our events page to see a complete list of events in the prostate cell community.
NEW Scientific Officer – Prostate Oncobiology Group (Cancer Research UK Manchester Institute)

NEW Postdoctoral Fellow – Abnormal DNA Methylation on Prostate Cancer Aggressiveness (Cleveland Clinic)

Scientific Officer – Prostate Oncobiology (Cancer Research UK Manchester Institute)

Postdoctoral Position – Prostate Cell Biology & Cancer (Commissariat à l’Energie Atomique (CEA))

Postdoctoral Fellow – Genitourinary Cancers (Geisinger Health System)

Cancer Biologist (Wake Forest Baptist Medical Center)

Postdoctoral Research Fellow – Prostate Cancer and Breast Cancer (Baylor College of Medicine)

Postdoctoral Fellow – Development, Progression and Chemotherapy Resistance of Cancers (University of Maryland School of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us